Health Highlights: Aug. 22, 2005
Posted on: Monday, 22 August 2005, 09:00 CDT
Here are some of the latest health and medical news developments, compiled by the editors of HealthDay:
Paxil Linked to Adult Suicide Rise, Review Contends
The antidepressant Paxil is linked to a higher risk of suicide attempts in adults, according to a review of 16 studies by researchers in Norway.
The review, published in BMC Medicine journal, looked at adult patients in studies comparing the medicine with a placebo. The researchers, led by Ivar Aursnes and colleagues at the University of Oslo, found seven suicide attempts among those taking Paxil (paroxetine), compared with one among those taking a placebo, they said in an e-mailed statement to Bloomberg news.
In April, European health regulators warned that GlaxoSmithKline's Paxil, Eli Lilly & Co.'s Prozac and other antidepressants shouldn't be used to treat children due to a risk of suicide. Aursnes said his study may persuade doctors and regulators to more closely monitor all use of the drug.
Glaxo officials, who hadn't seen the study, said they will review the paper, which looked at 916 patients taking Paxil and 550 patients on placebo.
"These conclusions in no way reflect the picture that has been built up about the benefits and risks of paroxetine in adults through an extensive clinical trials program involving 24,000 patients," Glaxo spokesman Chris Hunter-Ward said.
-----
Gene Fragments Could Fight SARS
As reported by the Associated Press, genetic material called interfering RNA could be a key weapon against severe acute respiratory syndrome (SARS), a team of Chinese and U.S. researchers reported Sunday.
SARS, which first emerged in 2002, raised global health alarms and killed 774 people worldwide before it was contained.
Reporting in Nature Medicine, researchers led by Patrick Yu of Intradigm Corp., of Rockville, Md., say tiny gene snippets known as siRNA effectively silenced specific genes in the SARS genome-- reducing existing infection in monkeys and helping protect the animals from new SARS infections.
All of the treated monkeys did show some symptoms, but they were greatly reduced after treatment with an siRNA nasal spray, the researchers said. Throat samples taken four days after infection found evidence of SARS virus in only a quarter of animals receiving the gene-based treatment.
Speaking to the AP, SARS expert Dr. Krishan K. Pandey of the University of Minnesota, said the success of the treatment in monkeys is impressive, since they are such close genetic relatives of humans. "Another strong point of this study is the successful use of siRNA in prophylactic treatment of SARS, which is surely a great thing if it is successful in humans," he said.
-----
Immune Discovery Could Lead to Blood Cancer Vaccine
An experimental vaccine appears to prime the human immune system to fight an aggressive form of lymphoma, even if prior therapy has depleted nearly all the B cells thought necessary to this type of immune response.
Reporting in Nature Medicine on Sunday, researchers at the National Cancer Institute in Bethesda, Md, and the M.D. Anderson Cancer Center in Houston, found that only a tiny number of B cells were needed to trigger an effective response in killer T cells.
Before this study, experts assumed that relatively high amounts of both cell types were needed to spur a vaccine-like attack on lymphomas.
"This is the first human cancer vaccine study to see T-cell responses in the absence of B cells, and this paves the way to use vaccines in a number of hematological cancers that are treated by eliminating diseased B cells," study lead author Dr. Sattva Neelapu, of the M.D. Anderson Cancer Center, said in a prepared statement.
His team's Phase I trial of the vaccine against deadly mantle cell lymphoma noted T-cell responses following the third vaccination. Furthermore, "an antibody response to the tumor produced by recovering B cells was seen after the fourth or fifth vaccination," Neepalu said.
While some patients have relapsed while on the therapy, others have survived, suggesting the vaccine "did modify the natural history of the disease," the Texas researcher said. His team is now working to improve the vaccine with the aim of testing it further.
-----
Being Kind to Oneself Helps People Deal With Failure
Self-compassion -- treating yourself with the same kindness you'd show a friend in need -- may be more important than self-esteem in helping to cope with failure, new research shows.
In three different studies, Wake Forest University psychologist Mark Leary had participants either imagine past failures, or put them in situations where they felt as if they were sub-par.
In all cases, simply being kind to themselves despite failure -- thinking "Everybody goofs up now and then," for example -- helped people feel less unhappy or angry after experiencing letdown or shame.
In addition, "Highly self-compassionate people actually took more responsibility for their shortcomings and problems," Leary said in a statement. "Because they didn't beat themselves up when things went badly for them, they were able to admit their mistakes."
Leary presented the findings Saturday at the annual meeting of the American Psychological Association in Washington, D.C.
~PRSS~
Source: HealthSCOUT
Related Articles
- Multiple Sclerosis Patient Finds Hope Through Stem Cell Treatment
- Stem Cell Treatment for Babies with Brittle Bones
- Stem-Cell Treatment for MS Tested
- New Stem Cell Treatment Tested for Clogged Arteries
- Don Ho Recovering after Stem Cell Treatment
- Icagen Reports Results of Phase II Open Label Extension Study of ICA-17043 for the Treatment of Sickle Cell Anemia
- [ HEART Disease Victim Given Pioneering Stem Cell Treatment... ]
- Winston Says Stem Cell Treatments 'Hyped Up
- Study: Experimental Cancer Treatments Help
- Nabi Biopharmaceuticals Announces Initiation of New StaphVAX(R) Immunogenicity Study in Orthopedic Surgery Patients
User Comments (0)


RSS Feeds